The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced non-small-cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. standard inverse sequence. The trial, designed to test noninferiority in overall survival, was stopped at interim analysis because of inferior survival in the experimental arm. Quality of life (QoL), a secondary outcome, is reported here.
|Numero di pagine||15|
|Rivista||Journal of Thoracic Oncology|
|Stato di pubblicazione||Published - 2012|
- Pulmonary and Respiratory Medicine